Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program.

Stein EA, Vidt DG, Shepherd J, Cain VA, Anzalone D, Cressman MD.

Atherosclerosis. 2012 Apr;221(2):471-7. doi: 10.1016/j.atherosclerosis.2011.12.011. Epub 2012 Jan 3.

PMID:
22304793
2.
3.
4.

Rosuvastatin: a risk-benefit assessment for intensive lipid lowering.

Ferdinand KC.

Expert Opin Pharmacother. 2005 Sep;6(11):1897-910. Review.

PMID:
16144509
5.

Safety of rosuvastatin.

Shepherd J, Hunninghake DB, Stein EA, Kastelein JJ, Harris S, Pears J, Hutchinson HG.

Am J Cardiol. 2004 Oct 1;94(7):882-8.

PMID:
15464670
6.

Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.

Mazza F, Stefanutti C, Di Giacomo S, Vivenzio A, Fraone N, Mazzarella B, Bucci A.

Am J Cardiovasc Drugs. 2008;8(4):265-70.

PMID:
18690760
7.

Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).

Deedwania PC, Gupta M, Stein M, Ycas J, Gold A; IRIS Study Group.

Am J Cardiol. 2007 Jun 1;99(11):1538-43. Epub 2007 Apr 16.

PMID:
17531577
8.
9.

Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.

Wlodarczyk J, Sullivan D, Smith M.

Am J Cardiol. 2008 Dec 15;102(12):1654-62. doi: 10.1016/j.amjcard.2008.08.014. Epub 2008 Sep 20.

PMID:
19064019
11.

Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin.

Willich SN, Englert H, Sonntag F, Völler H, Meyer-Sabellek W, Wegscheider K, Windler E, Katus H, Müller-Nordhorn J.

Eur J Cardiovasc Prev Rehabil. 2009 Apr;16(2):180-7. doi: 10.1097/HJR.0b013e3283262ac3.

PMID:
19174696
12.

Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate.

Vidt DG, Harris S, McTaggart F, Ditmarsch M, Sager PT, Sorof JM.

Am J Cardiol. 2006 Jun 1;97(11):1602-6. Epub 2006 Apr 7.

PMID:
16728222
13.

Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia.

Saito Y, Goto Y, Dane A, Strutt K, Raza A.

J Atheroscler Thromb. 2003;10(6):329-36.

14.

One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.

Ferdinand KC, Davidson MH, Kelly MT, Setze CM.

Am J Cardiovasc Drugs. 2012 Apr 1;12(2):117-25. doi: 10.2165/11597940-000000000-00000.

PMID:
22263674
15.
16.
17.

Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program.

Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J.

Cardiology. 2007;107(4):433-43. Epub 2007 Mar 16.

PMID:
17363845
18.

Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study.

Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, Sosef F; ECLIPSE Study Investigators.

Cardiology. 2008;111(4):219-28. doi: 10.1159/000127442. Epub 2008 Apr 23.

PMID:
18434729
19.

Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER).

Everett BM, Mora S, Glynn RJ, MacFadyen J, Ridker PM.

Am J Cardiol. 2014 Dec 1;114(11):1682-9. doi: 10.1016/j.amjcard.2014.08.041. Epub 2014 Sep 16.

PMID:
25439449

Supplemental Content

Support Center